search icon
nrbo-img

Neurobo Pharmaceuticals Inc, Common Stock

NRBO

NAQ

$

+$

(%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$20.33M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.28
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.51 L
$6.75 H
$

About Neurobo Pharmaceuticals Inc, Common Stock

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNRBOSectorS&P500

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue----7.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue17.00K67.00K72.00K28.00K7.00K[{"date":"2019-12-31","value":23.61,"profit":true},{"date":"2020-12-31","value":93.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":38.89,"profit":true},{"date":"2023-12-31","value":9.72,"profit":true}]
Gross Profit(17.00K)(67.00K)(72.00K)(28.00K)-[{"date":"2019-12-31","value":-1700000,"profit":false},{"date":"2020-12-31","value":-6700000,"profit":false},{"date":"2021-12-31","value":-7200000,"profit":false},{"date":"2022-12-31","value":-2800000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)-[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses20.18M29.72M15.30M11.42M15.89M[{"date":"2019-12-31","value":67.9,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":51.48,"profit":true},{"date":"2022-12-31","value":38.42,"profit":true},{"date":"2023-12-31","value":53.46,"profit":true}]
Operating Income(20.18M)(29.72M)(15.30M)(19.63M)(15.89M)[{"date":"2019-12-31","value":-2017600000,"profit":false},{"date":"2020-12-31","value":-2971600000,"profit":false},{"date":"2021-12-31","value":-1529800000,"profit":false},{"date":"2022-12-31","value":-1962800000,"profit":false},{"date":"2023-12-31","value":-1588600000,"profit":false}]
Total Non-Operating Income/Expense(1.16M)77.00K28.00K3.47M1.39M[{"date":"2019-12-31","value":-33.37,"profit":false},{"date":"2020-12-31","value":2.22,"profit":true},{"date":"2021-12-31","value":0.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":39.97,"profit":true}]
Pre-Tax Income(21.31M)(29.68M)(15.28M)(13.97M)(12.47M)[{"date":"2019-12-31","value":-2131200000,"profit":false},{"date":"2020-12-31","value":-2967800000,"profit":false},{"date":"2021-12-31","value":-1528400000,"profit":false},{"date":"2022-12-31","value":-1396700000,"profit":false},{"date":"2023-12-31","value":-1247000000,"profit":false}]
Income Taxes1.12M(85.00K)(62.00K)(7.85M)-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7.6,"profit":false},{"date":"2021-12-31","value":-5.54,"profit":false},{"date":"2022-12-31","value":-701.7,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(22.43M)(29.59M)(15.22M)(6.12M)-[{"date":"2019-12-31","value":-2243100000,"profit":false},{"date":"2020-12-31","value":-2959300000,"profit":false},{"date":"2021-12-31","value":-1522200000,"profit":false},{"date":"2022-12-31","value":-611500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(21.31M)(29.68M)(15.28M)(13.97M)(11.83M)[{"date":"2019-12-31","value":-2131200000,"profit":false},{"date":"2020-12-31","value":-2967800000,"profit":false},{"date":"2021-12-31","value":-1528400000,"profit":false},{"date":"2022-12-31","value":-1396700000,"profit":false},{"date":"2023-12-31","value":-1183200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(22.43M)(29.59M)(15.22M)(6.12M)(12.47M)[{"date":"2019-12-31","value":-2243100000,"profit":false},{"date":"2020-12-31","value":-2959300000,"profit":false},{"date":"2021-12-31","value":-1522200000,"profit":false},{"date":"2022-12-31","value":-611500000,"profit":false},{"date":"2023-12-31","value":-1247000000,"profit":false}]
EPS (Diluted)(263.85)(55.20)(51.39)(5.61)(2.49)[{"date":"2019-12-31","value":-26385,"profit":false},{"date":"2020-12-31","value":-5520,"profit":false},{"date":"2021-12-31","value":-5139,"profit":false},{"date":"2022-12-31","value":-561,"profit":false},{"date":"2023-12-31","value":-249,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NRBO
Cash Ratio 2.38
Current Ratio 2.41

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NRBO
ROA (LTM) -74.35%
ROE (LTM) -160.76%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NRBO
Debt Ratio Lower is generally better. Negative is bad. 0.42
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.58

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NRBO
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.36
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Neurobo Pharmaceuticals Inc share price today?

Neurobo Pharmaceuticals Inc (NRBO) share price today is $

Can Indians buy Neurobo Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Neurobo Pharmaceuticals Inc (NRBO) on Vested. To buy Neurobo Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NRBO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Neurobo Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Neurobo Pharmaceuticals Inc (NRBO) via the Vested app. You can start investing in Neurobo Pharmaceuticals Inc (NRBO) with a minimum investment of $1.

How to invest in Neurobo Pharmaceuticals Inc shares from India?

You can invest in shares of Neurobo Pharmaceuticals Inc (NRBO) via Vested in three simple steps:

  • Click on Sign Up or Invest in NRBO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Neurobo Pharmaceuticals Inc shares
What is Neurobo Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Neurobo Pharmaceuticals Inc (NRBO) is $6.75. The 52-week low price of Neurobo Pharmaceuticals Inc (NRBO) is $1.51.

What is Neurobo Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Neurobo Pharmaceuticals Inc (NRBO) is

What is Neurobo Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Neurobo Pharmaceuticals Inc (NRBO) is 1.36

What is Neurobo Pharmaceuticals Inc dividend yield?

The dividend yield of Neurobo Pharmaceuticals Inc (NRBO) is 0.00%

What is the Market Cap of Neurobo Pharmaceuticals Inc?

The market capitalization of Neurobo Pharmaceuticals Inc (NRBO) is $20.33M

What is Neurobo Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Neurobo Pharmaceuticals Inc is NRBO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top